30-July-2007:  Amira Pharmaceuticals Announces Appointment of First Chief Executive Officer Amira Pharmaceuticals, a small molecule pharmaceutical company focused on the discovery and development of compounds to treat inflammatory disease linked to the eicosanoid pathway, today announced that the company has appointed Robert F. Baltera, Jr., as the company’s first chief executive officer, effective immediately.<more> or download <PDF>

16-July-2007:  Amira Pharmaceuticals Announces Positive Initial Data from a Phase 1 Study of AM103, A Novel Product Candidate for the Treatment of Respiratory and Cardiovascular Disease.  Amira Pharmaceuticals today announced initial, positive data from a Phase 1 clinical trial of AM103, the company’s lead compound. The early, interim results demonstrate that a single dose of AM103 achieves highly significant inhibition of leukotriene synthesis. <more> or download <PDF>

23-Mar-2007: Amira Pharmaceuticals Raises $25 Million in Series B Financing. 
Amira Pharmaceuticals today announced that it has raised $25 million in a private equity financing led by Novo A/S. Additional investors in the Series B round included Avalon Ventures, Prospect Venture Partners and Versant Ventures, all founding investors.<more>

2006

01-Nov-2006: Research collaboration with Roche reaches first milestone ahead of schedule.  Amira Pharmaceuticals today announced its first milestone payment from pharmaceutical partner Roche just nine months after the start of their research collaboration. <more>

09-Jan-2006: Roche and Amira Pharmaceuticals announce innovative alliance model 
Swiss healthcare group Roche and San Diego based biotech company Amira Pharmaceuticals today announced a pioneering model for collaboration consisting of a research alliance and an option for Amira to license two clinical stage compounds from Roche.<more>

Previous